{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:12011"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:12011","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"GPNMB: exploring a novel target for therapy in Hodgkin lymphoma","abstract":"Glycoprotein non-metastatic melanoma protein B (GPNMB) is a transmembrane protein highly expressed in multiple tumours, including classical Hodgkin lymphoma (cHL); a tumour in which the malignant Hodgkin and Reed-Sternberg (HRS) cells rely on the tumour microenvironment (TME) to survive and evade detection by the host immune system. In this study, I explore the contribution of GPNMB to immune evasion of cHL as a novel therapeutic target. I have shown that GPNMB is highly expressed in tumour-associated macrophages (TAM) in cHL tissues but expression is highly variable. In vitro differentiation of macrophages (from CD14\\(^+\\) monocytes) was shown to be associated with an increase in GPNMB expression, including the generation of a soluble form of GPNMB (sGPNMB). sGPNMB partially inhibited T-cell activation and T-cell recognition of Epstein-Barr virus (EBV)-specific epitopes in cHL cell lines. Preliminary experiments indicated that the inhibition of T cell activation by GPNMB could be overcome with GPNMB neutralising antibodies. This work provides evidence in support of the hypothesis that GPNMB can mediate an immune checkpoint that inhibits anti-tumour cytotoxic T-lymphocytes (CTL). It provides a basis for further investigations designed to explore the therapeutic potential of targeting GPNMB in cHL.","abstract_html":"Glycoprotein non-metastatic melanoma protein B (GPNMB) is a transmembrane protein highly expressed in multiple tumours, including classical Hodgkin lymphoma (cHL); a tumour in which the malignant Hodgkin and Reed-Sternberg (HRS) cells rely on the tumour microenvironment (TME) to survive and evade detection by the host immune system. In this study, I explore the contribution of GPNMB to immune evasion of cHL as a novel therapeutic target. I have shown that GPNMB is highly expressed in tumour-associated macrophages (TAM) in cHL tissues but expression is highly variable. In vitro differentiation of macrophages (from CD14<span class=\"etd-inline-math\"><sup>+</sup></span> monocytes) was shown to be associated with an increase in GPNMB expression, including the generation of a soluble form of GPNMB (sGPNMB). sGPNMB partially inhibited T-cell activation and T-cell recognition of Epstein-Barr virus (EBV)-specific epitopes in cHL cell lines. Preliminary experiments indicated that the inhibition of T cell activation by GPNMB could be overcome with GPNMB neutralising antibodies. This work provides evidence in support of the hypothesis that GPNMB can mediate an immune checkpoint that inhibits anti-tumour cytotoxic T-lymphocytes (CTL). It provides a basis for further investigations designed to explore the therapeutic potential of targeting GPNMB in cHL.","abstract_has_math":true,"creators":["Masand, Navta"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2021,"date_issued":"2021-12","date_published":"2021-12","updated_at":"2026-11-19T09:31:36Z","subjects":["Q Science (General)","R Medicine (General)","RM Therapeutics. Pharmacology"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.grantnumber","label":"Dc Identifier Grantnumber","values":["BCHRF457","CCLGA 2017 18"],"render_values":[{"text":"BCHRF457","href":null,"code":true},{"text":"CCLGA 2017 18","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/12011/7/MASAND2021PhD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A12011","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["other"]},{"key":"dc:creator","label":"Author","values":["Masand, Navta"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2021-12-10"]},{"key":"dc:date.issued","label":"Date","values":["2021-12"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Cancer and Genomic Sciences"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/12011/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Q Science (General)","R Medicine (General)","RM Therapeutics. Pharmacology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.grantnumber","label":"Dc Identifier Grantnumber","values":["BCHRF457","CCLGA 2017 18"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/12011/7/MASAND2021PhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Glycoprotein non-metastatic melanoma protein B (GPNMB) is a transmembrane protein highly expressed in multiple tumours, including classical Hodgkin lymphoma (cHL); a tumour in which the malignant Hodgkin and Reed-Sternberg (HRS) cells rely on the tumour microenvironment (TME) to survive and evade detection by the host immune system. In this study, I explore the contribution of GPNMB to immune evasion of cHL as a novel therapeutic target. I have shown that GPNMB is highly expressed in tumour-associated macrophages (TAM) in cHL tissues but expression is highly variable. In vitro differentiation of macrophages (from CD14\\(^+\\) monocytes) was shown to be associated with an increase in GPNMB expression, including the generation of a soluble form of GPNMB (sGPNMB). sGPNMB partially inhibited T-cell activation and T-cell recognition of Epstein-Barr virus (EBV)-specific epitopes in cHL cell lines. Preliminary experiments indicated that the inhibition of T cell activation by GPNMB could be overcome with GPNMB neutralising antibodies. This work provides evidence in support of the hypothesis that GPNMB can mediate an immune checkpoint that inhibits anti-tumour cytotoxic T-lymphocytes (CTL). It provides a basis for further investigations designed to explore the therapeutic potential of targeting GPNMB in cHL."]},{"key":"dc:format","label":"Dc Format","values":["text"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["GPNMB: exploring a novel target for therapy in Hodgkin lymphoma"]}]}],"canonical_facts":{"dc:contributor.sponsor":["other"],"dc:creator":["Masand, Navta"],"dc:date":["2021-12-10"],"dc:date.issued":["2021-12"],"dc:description.abstract":["Glycoprotein non-metastatic melanoma protein B (GPNMB) is a transmembrane protein highly expressed in multiple tumours, including classical Hodgkin lymphoma (cHL); a tumour in which the malignant Hodgkin and Reed-Sternberg (HRS) cells rely on the tumour microenvironment (TME) to survive and evade detection by the host immune system. In this study, I explore the contribution of GPNMB to immune evasion of cHL as a novel therapeutic target. I have shown that GPNMB is highly expressed in tumour-associated macrophages (TAM) in cHL tissues but expression is highly variable. In vitro differentiation of macrophages (from CD14\\(^+\\) monocytes) was shown to be associated with an increase in GPNMB expression, including the generation of a soluble form of GPNMB (sGPNMB). sGPNMB partially inhibited T-cell activation and T-cell recognition of Epstein-Barr virus (EBV)-specific epitopes in cHL cell lines. Preliminary experiments indicated that the inhibition of T cell activation by GPNMB could be overcome with GPNMB neutralising antibodies. This work provides evidence in support of the hypothesis that GPNMB can mediate an immune checkpoint that inhibits anti-tumour cytotoxic T-lymphocytes (CTL). It provides a basis for further investigations designed to explore the therapeutic potential of targeting GPNMB in cHL."],"dc:format":["text"],"dc:identifier.grantnumber":["BCHRF457","CCLGA 2017 18"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/12011/7/MASAND2021PhD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Cancer and Genomic Sciences"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/12011/"],"dc:subject":["Q Science (General)","R Medicine (General)","RM Therapeutics. Pharmacology"],"dcterms:accessrights":["public"],"dc:title":["GPNMB: exploring a novel target for therapy in Hodgkin lymphoma"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"]},"updated_at":"2026-11-19T09:31:36Z"}